NASDAQ:SANA - Nasdaq - US7995661045 - Common Stock - Currency: USD
SANA BIOTECHNOLOGY INC
NASDAQ:SANA (1/24/2025, 2:12:46 PM)
3.49
0 (0%)
The current stock price of SANA is 3.49 USD. In the past month the price increased by 111.52%. In the past year, price decreased by -36.2%.
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
What's going on in today's session
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Get insights into the top gainers and losers of Wednesday's pre-market session.
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University...
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 15.89 | 301.92B | ||
AMGN | AMGEN INC | 14.4 | 148.79B | ||
GILD | GILEAD SCIENCES INC | 21.11 | 116.56B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 860.78 | 113.06B | ||
REGN | REGENERON PHARMACEUTICALS | 15.01 | 74.92B | ||
ARGX | ARGENX SE - ADR | N/A | 39.06B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.76B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.89B | ||
ONC | BEIGENE LTD-ADR | N/A | 23.67B | ||
NTRA | NATERA INC | N/A | 22.24B | ||
BIIB | BIOGEN INC | 8.86 | 21.08B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.71B |
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 328 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. The company is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. The company is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. The company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.
SANA BIOTECHNOLOGY INC
188 East Blaine Street, Suite 400
Seattle WASHINGTON 98102 US
CEO: Steven D. Harr
Employees: 328
Company Website: https://sana.com/
Investor Relations: https://ir.sana.com/
Phone: 12067017914
The current stock price of SANA is 3.49 USD.
The exchange symbol of SANA BIOTECHNOLOGY INC is SANA and it is listed on the Nasdaq exchange.
SANA stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SANA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SANA.
SANA does not pay a dividend.
SANA does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.36).
The outstanding short interest for SANA is 18.24% of its float.
ChartMill assigns a technical rating of 4 / 10 to SANA. When comparing the yearly performance of all stocks, SANA is a bad performer in the overall market: 87.9% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to SANA. While SANA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SANA reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS increased by 1.45% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -54.67% | ||
ROE | -104.56% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to SANA. The Buy consensus is the average rating of analysts ratings from 13 analysts.